LIVER

Adiponectin and its receptors in non-alcoholic steatohepatitis

S Kaser¹, A Moschen², A Cayon³, A Kaser², J Crespo³, F Pons-Romero³, C F Ebenbichler¹, J R Patsch¹, H Tilg²

¹ University Hospital Innsbruck, Department of Medicine, Division of General Internal Medicine, Innsbruck, Austria
² University Hospital Innsbruck, Department of Medicine, Division of Gastroenterology and Hepatology, Innsbruck, Austria
³ University Hospital Marques de Valdecilla, School of Medicine, Institute of Digestive Diseases, Santander, Spain

Correspondence to:
Correspondence to:
Dr H Tilg
University Hospital Innsbruck, Department of Medicine, Division of Gastroenterology and Hepatology, Anichstrasse 35, 6020 Innsbruck, Austria; herbert.tilg{at}uibk.ac.at

Background: Adiponectin, an adipocyte derived polypeptide, has been shown to alleviate steatosis and inflammation in mice with non-alcoholic fatty liver disease.

Aim: In the present study, we wished to define liver expression of adiponectin and its receptors in morbidly obese patients undergoing bariatric surgery. Patients with non-alcoholic steatohepatitis (NASH) or simple steatosis were investigated to test whether dysregulation of this system might be involved in these disorders.

Patients and methods: Liver mRNA expression of adiponectin and its recently cloned receptors RI and RII (adipoRI and adipoRII) were analysed by fluorescence based real time polymerase chain reaction in 13 patients with NASH and nine with simple steatosis. Adiponectin and adipoRII protein expression were assessed by immunohistochemistry in a subgroup of patients.

Results: Adiponectin and adipoRII mRNA expression were significantly reduced in liver biopsies of patients with NASH compared with simple steatosis while no difference was found in adipoRI mRNA expression. In NASH, adipoRII mRNA expression was negatively correlated with serum aspartate aminotransferase levels, serum alanine aminotransferase levels, and grade of fibrosis. Liver adiponectin protein expression was mainly found in endothelial cells of portal vessels and liver sinusoids whereas adipoRII expression was seen in hepatocytes only. Adiponectin and adipoRII staining were lower in biopsies of subjects with NASH compared with simple steatosis.

Conclusion: Reduced hepatic expression of adiponectin and adipoRII might be of pathophysiological relevance in non-alcoholic fatty liver diseases.

Abbreviations: NASH, non-alcoholic steatohepatitis; adipoRI, adiponectin receptor I; adipoRII, adiponectin receptor II; AST, aspartate aminotransferase; ALT, alanine aminotransferase; -GT, gamma glutamyl transferase; IL, interleukin; TNF, tumour necrosis factor; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; PPAR, peroxisome proliferator activated receptor; HOMA, homeostasis model assessment

Keywords: non-alcoholic steatohepatitis; adiponectin; obesity

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Dowman, J. K., Tomlinson, J.W., Newsome, P.N. (2009). Pathogenesis of non-alcoholic fatty liver disease. QJM 0: hcp158v1-hcp158 [Full Text]  
• Rahman, S. M., Qadri, I., Janssen, R. C., Friedman, J. E. (2009). Fenofibrate and PBA prevent fatty acid-induced loss of adiponectin receptor and pAMPK in human hepatoma cells and in hepatitis C virus-induced steatosis. J. Lipid Res. 50: 2193-2202 [Abstract] [Full Text]  
• Kotronen, A., Yki-Jarvinen, H., Aminoff, A., Bergholm, R., Pietilainen, K. H, Westerbacka, J., Talmud, P. J, Humphries, S. E, Hamsten, A., Isomaa, B., Groop, L., Orho-Melander, M., Ehrenborg, E., Fisher, R. M (2009). Genetic variation in the ADIPOR2 gene is associated with liver fat content and its surrogate markers in three independent cohorts. Eur J Endocrinol 160: 593-602 [Abstract] [Full Text]  
• Taksali, S. E., Caprio, S., Dziura, J., Dufour, S., Cali, A. M.G., Goodman, T. R., Papademetris, X., Burgert, T. S., Pierpont, B. M., Savoye, M., Shaw, M., Seyal, A. A., Weiss, R. (2008). High Visceral and Low Abdominal Subcutaneous Fat Stores in the Obese Adolescent: A Determinant of an Adverse Metabolic Phenotype. Diabetes 57: 367-371 [Abstract] [Full Text]  
• Liu, L.-F., Purushotham, A., Wendel, A. A., Belury, M. A. (2007). Combined effects of rosiglitazone and conjugated linoleic acid on adiposity, insulin sensitivity, and hepatic steatosis in high-fat-fed mice. Am. J. Physiol. Gastrointest. Liver Physiol. 292: G1671-G1682 [Abstract] [Full Text]  
• Bertolani, C., Sancho-Bru, P., Failli, P., Bataller, R., Aleffi, S., DeFranco, R., Mazzinghi, B., Romagnani, P., Milani, S., Gines, P., Colmenero, J., Parola, M., Gelmini, S., Tarquini, R., Laffi, G., Pinzani, M., Marra, F. (2006). Resistin as an Intrahepatic Cytokine: Overexpression during Chronic Injury and Induction of Proinflammatory Actions in Hepatic Stellate Cells. Am. J. Pathol. 169: 2042-2053 [Abstract] [Full Text]  
• Belfort, R., Harrison, S. A., Brown, K., Darland, C., Finch, J., Hardies, J., Balas, B., Gastaldelli, A., Tio, F., Pulcini, J., Berria, R., Ma, J. Z., Dwivedi, S., Havranek, R., Fincke, C., DeFronzo, R., Bannayan, G. A., Schenker, S., Cusi, K. (2006). A Placebo-Controlled Trial of Pioglitazone in Subjects with Nonalcoholic Steatohepatitis. NEJM 355: 2297-2307 [Abstract] [Full Text]  
• Touyz, R. M. (2005). Endothelial Cell IL-8, a New Target for Adiponectin: Implications in Vascular Protection. Circ. Res. 97: 1216-1219 [Full Text]  
• Adams, L. A., Angulo, P., Lindor, K. D. (2005). Nonalcoholic fatty liver disease. CMAJ 173: 735-735 [Full Text]  
• Bugianesi, E., Pagotto, U., Manini, R., Vanni, E., Gastaldelli, A., de Iasio, R., Gentilcore, E., Natale, S., Cassader, M., Rizzetto, M., Pasquali, R., Marchesini, G. (2005). Plasma Adiponectin in Nonalcoholic Fatty Liver Is Related to Hepatic Insulin Resistance and Hepatic Fat Content, Not to Liver Disease Severity. J. Clin. Endocrinol. Metab. 90: 3498-3504 [Abstract] [Full Text]  

eLetters:

Read all eLetters

Adiponectin receptor II in non-alcoholic fatty liver disease

Toshinari Takamura, et al.

Gut Online, 16 Mar 2005 [Full text]